FIELD: medicine.
SUBSTANCE: invention refers to medicine, and concerns a diagnostic technique for prostate cancer involving sample analysis for the presence and/or the amount of annexin A3 with using a monoclonal antibody specific to annexin A3 of low cross reactivity to the other annexins and aiming at an N-terminal of annexin A3, especially on an epitope in the region of amino acid of 1-16 human annexin A3. Also, the invention refers to a reagent for diagnosing prostate cancer containing such antibodies.
EFFECT: invention provides a technique for detecting prostate carcinoma enabling high-specific early diagnosis.
9 cl, 5 ex, 15 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANNEXIN A3 AUTOIMMUNE REGULATION OF PROSTATE CANCER | 2008 |
|
RU2484482C2 |
| PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPEUTIC REGIMENS BASED ON VACCINES | 2013 |
|
RU2737765C2 |
| PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPY SCHEMES BASED ON VACCINES | 2013 |
|
RU2609651C2 |
| USING MVA (MODIFIED VACCINIA ANKARA) FOR TREATING PROSTATE CANCER | 2008 |
|
RU2499606C2 |
| TREATMENTS OF CANCER EXPRESSING MUTANT EGF RECEPTORS | 2007 |
|
RU2429014C2 |
| ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | 2012 |
|
RU2658603C2 |
| CANCER BIOMARKERS | 2007 |
|
RU2460075C2 |
| COMBINED THERAPY USING THE ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2665321C2 |
| SPECIFIC ANTIBODY TO S100A4 OR ITS FRAGMENT (VERSIONS), METHOD OF PRODUCTION THEREOF (VERSIONS), PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUNDS, HYBRIDOMA CELL LINE (VERSIONS), CONJUGATE, COMPOSITION, METHOD OF PREVENTING AND/OR TREATING CANCER, METASTASIS, ANGIOGENESIS AND INFLAMMATORY DISEASES, METHOD AND KIT FOR DIAGNOSING CANCER OR DISEASE ASSOCIATED WITH INFLAMMATION (VERSIONS), METHOD OF DETECTING S100A4, METHOD OF MAKING INDIVIDUAL THERAPY | 2011 |
|
RU2615684C2 |
| COMBINED THERAPY WITH USE OF CLAUDIN 18,2 ANTIBODIES FOR CANCER TREATMENT | 2013 |
|
RU2662066C2 |
